Ozempic Patent Protection
33 patents · Novo Nordisk A/S
Patent Details
| Patent # | Title | Assignee | Expires | Status |
|---|---|---|---|---|
| 10357616 | Drug product (formulation / method-of-use) patent | Novo Nordisk A/S | Jan 20, 2026 | Expired |
| 9108002 | Drug product (formulation / method-of-use) patent | Novo Nordisk A/S | Jan 20, 2026 | Expired |
| 10376652 | Drug product (formulation / method-of-use) patent | Novo Nordisk A/S | Jan 20, 2026 | Expired |
| 9861757 | Drug product (formulation / method-of-use) patent | Novo Nordisk A/S | Jan 20, 2026 | Expired |
| 9616180 | Drug product (formulation / method-of-use) patent | Novo Nordisk A/S | Jan 20, 2026 | Expired |
| 8536122 | Drug substance & product patent | Novo Nordisk A/S | Mar 20, 2026 | Expired |
| 11097063 | Drug product (formulation / method-of-use) patent | Novo Nordisk A/S | Jul 17, 2026 | 0.1y left |
| 9775953 | Drug product (formulation / method-of-use) patent | Novo Nordisk A/S | Jul 17, 2026 | 0.1y left |
| 8920383 | Drug product (formulation / method-of-use) patent | Novo Nordisk A/S | Jul 17, 2026 | 0.1y left |
| 10220155 | Drug product (formulation / method-of-use) patent | Novo Nordisk A/S | Jul 17, 2026 | 0.1y left |
| RE46363 | Drug product (formulation / method-of-use) patent | Novo Nordisk A/S | Aug 3, 2026 | 0.1y left |
| 9687611 | Drug product (formulation / method-of-use) patent | Novo Nordisk A/S | Feb 27, 2027 | 0.7y left |
| 9457154 | Drug product (formulation / method-of-use) patent | Novo Nordisk A/S | Sep 29, 2027 | 1.3y left |
| 8129343 | Drug substance & product patent | Novo Nordisk A/S | Dec 5, 2031 | 5.4y left |
| 9278123 | Drug substance & product patent | Novo Nordisk A/S | Dec 16, 2031 | 5.5y left |
| 11382957 | Drug substance & product patent | Novo Nordisk A/S | Dec 16, 2031 | 5.5y left |
| 10960052 | Drug product (formulation / method-of-use) patent | Novo Nordisk A/S | Dec 16, 2031 | 5.5y left |
| 10086047 | Drug product (formulation / method-of-use) patent | Novo Nordisk A/S | Dec 16, 2031 | 5.5y left |
| 9132239 | Drug product (formulation / method-of-use) patent | Novo Nordisk A/S | Feb 1, 2032 | 5.6y left |
| 10933120 | Drug product (formulation / method-of-use) patent | Novo Nordisk A/S | Mar 15, 2033 | 6.7y left |
| 11759501 | Drug product (formulation / method-of-use) patent | Novo Nordisk A/S | Mar 15, 2033 | 6.7y left |
| 11759502 | Drug product (formulation / method-of-use) patent | Novo Nordisk A/S | Mar 15, 2033 | 6.7y left |
| 11759503 | Drug product (formulation / method-of-use) patent | Novo Nordisk A/S | Mar 15, 2033 | 6.7y left |
| 12594326 | Drug product (formulation / method-of-use) patent | Novo Nordisk A/S | Mar 15, 2033 | 6.7y left |
| 11033499 | Drug product (formulation / method-of-use) patent | Novo Nordisk A/S | Jun 19, 2033 | 7.0y left |
| 10335462 | Drug product (formulation / method-of-use) patent | Novo Nordisk A/S | Jun 21, 2033 | 7.0y left |
| 10278923 | Drug substance & product patent | Novo Nordisk A/S | May 2, 2034 | 7.9y left |
| 12514822 | Orange Book listed patent | Novo Nordisk A/S | May 2, 2034 | 7.9y left |
| 12239739 | Drug substance & product patent | Novo Nordisk A/S | May 2, 2034 | 7.9y left |
| 12569543 | Orange Book listed patent | Novo Nordisk A/S | Apr 28, 2037 | 10.8y left |
| 12295988 | Orange Book listed patent | Novo Nordisk A/S | Oct 10, 2038 | 12.3y left |
| 11833248 | Drug product (formulation / method-of-use) patent | Novo Nordisk A/S | Feb 1, 2039 | 12.6y left |
| 12396953 | Drug product (formulation / method-of-use) patent | Novo Nordisk A/S | Feb 1, 2039 | 12.6y left |
Related Drug Patent Expirations
17 patents · earliest expires 2026 · Novo Nordisk A/S
17 patents · earliest expires 2026 · AstraZeneca AB
7 patents · earliest expires 2026 · Astellas Pharma Inc.
2 patents · earliest expires 2027 · Bristol-Myers Squibb Company
6 patents · earliest expires 2027 · Novartis AG
3 patents · earliest expires 2027 · Pfizer Inc.
The Ozempic record above pulls directly from the FDA Orange Book and USPTO patent records. What follows is the per-entity context — how Ozempic sits in the broader U.S. pharmaceutical patent expirations distribution and which underlying factors drive the headline numbers.
Every number on this page links back to the FDA Orange Book and USPTO patent records; the methodology page describes the inputs, refresh cadence, and known limitations of the underlying data product.
Practical use of this page is in combination with the comparison and ranking pages elsewhere on the site, which surface the same data for Ozempic’s peers within U.S. brand-name drugs. A single-entity reading without peer context can be misleading when an entity is an outlier on one axis but typical on another.